[Toward a conditional price for medicine?].
For the first time, and as an exceptional option, the 2012 LEEM-CEPS framework agreement introduces the notion of conditional prices in conventional practice. The contractualization of drug price according to changes in its value that could occur in "real world" enables the Payer and the Company to settle, in a predictable manner, the "bet" represented by first registration price setting. Its systematization is based on the ability to standardize the implementation and assessment of observational studies, whereas the analysis and sharing of the risk of value changes (depreciation, appreciation) are structuring elements of the contractualization. Ethical from both the payer's and patient's point of view, drug price conditionality on its value is impeded by compliance with legal and economic constraints for the company, that should be taken into account by legalising this latter's ability to influence it through observance or therapeutic education and by guaranteeing a sufficiently long period of revenues for the company.
Lilly France Bénélux, 24, boulevard Vital-Bouhot, 92521 Neuilly-sur-Seine cedex, France. Electronic address: baseilhac_eric@lilly.com.
E
E
Baseilhac
D003132:Commerce; D032982:Contracts; D017047:Cost Sharing; D016527:Drug Costs / Q000592:standards*; D011445:Prospective Payment System / Q000592:standards*
Adherence; Assessment; Conditional price; Conditionnalité; Incertitude; Innovation; Medicine; Médicament; Observance; Prix; Uncertainty; Valeur; Value; Évaluation